SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bharat H. Barai who wrote (351)1/2/1998 9:00:00 AM
From: RalphLStevens,MD  Read Replies (1) of 442
 
I couldn't resist SMTG on sale last week @ 4 3/8, and picked up some more myself.
I'd agree that the long-term future for Optro and its offspring will be bright, even though '97 was pretty bleak.
Baxter and Northfield will get to market first, but for reasons of safety and production costs, I believe SMTG's Optro will eventually dominate the market.
Looking further out, given the flexibility of SMTG's recombinant technology and their strong patent position, I'd expect polymerized Optro varients, with longer half-lives and diminished vasoactivity to become more and more utilized for a vast variety of ischemic indications.
Happy New Year to all!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News